深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 国家倡导的创新，旨在推动各行业掌握核心技术，为国家发展贡献力量。 迈瑞将继续秉持这一理念，努力提升自身实力，为国家的医疗事业和科技进 步做出更大贡献，同时争取早日实现医疗器械全球排名前十的市场地位。 问：公司究竟有什么独特的"绝招"和卓越的经营能力，能够在激烈的市 场竞争中取得出色的成绩，并保持这种差异化优势？这种优势是否能够长期 维持？ 证券代码：300760 证券简称：迈瑞医疗 编号：2025-004 深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 | | □分析师会议 特定对象调研 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系 | □新闻发布会 路演活动 | | 活动类别 | 现场参观 | | | 投资者开放日、券商策略会等 其他 | | 参与单位名 382 称及人员姓 | 家机构 名参与人员，详见附件清单。 713 | | 名 | | | 2025 时间 | 年 月 日、5 月 日、6 月 日、6 月 日、6 月 5 19-23 26-30 3-5 12-13 18-20 | | 日、6 | ...

本报记者 陈婷 赵毅 深圳报道 近日，迈瑞医疗（300760.SZ）发布2024年年报及2025年一季报。年报显示，2024年，迈瑞医疗营收约 367.26亿元，同比增长5.14%，净利润约116.68亿元，同比增长0.74%，均仅录得个位数增长，结束了此 前连续八年业绩两位数增长的局面。 "环比数据显示已出现反弹信号。自去年12月份以来，医疗设备的月度招标数据呈现持续复苏态势，不 过在当前的竞争环境下，从公开招标到收入确认的时间差显著拉长，因此今年上半年国内收入实际反映 的是去年招标的大幅下滑。虽然一季度公司国内业务同比下降超过20%，但环比去年四季度增长了50% 以上。"迈瑞医疗方面对记者表示。 迈瑞医疗主要从事医疗器械的研发、制造、营销及服务，主要产品覆盖生命信息与支持、体外诊断及医 学影像三大业务领域。2024年，公司体外诊断业务收入体量首次超过生命信息与支持业务，达137.65亿 元，同比增长10.82%，占比约37.5%，其中国际体外诊断业务收入同比增长超过30%。 过去数年间，迈瑞医疗通过外延并购将其产业做大做强，同时通过自主研发强化其核心竞争力，公司迅 速成长为行业龙头企业。不过，自2020年 ...

Financial Performance - In 2024, the company achieved total revenue of 36.726 billion CNY, a year-on-year increase of 5.14% [2] - The net profit attributable to shareholders was 11.668 billion CNY, up 0.74% year-on-year; excluding financial expenses, the net profit growth was 4.36% [2] - Operating cash flow reached 12.432 billion CNY, reflecting a year-on-year increase of 12.38% [2] - For Q1 2025, total revenue was 8.237 billion CNY, a decline of 12.12% compared to the same period last year, with net profit down 16.81% [9] Dividend Distribution - The company plans to distribute 679 million CNY (including tax) as dividends for 2024, with a cumulative cash dividend of 7.602 billion CNY, representing a payout ratio of 65.15% [3] - A proposal for a mid-year dividend of 1.71 billion CNY (including tax) for 2025 is also in place, pending shareholder approval [3] Market Performance International Market - The international market grew by 21.28% in 2024, with the Asia-Pacific region seeing nearly 40% growth driven by countries like Australia, Thailand, and India [4] - International revenue accounted for approximately 45% of total revenue, with high-potential segments like minimally invasive surgery and cardiovascular care nearing 10% of international income [4] Domestic Market - The domestic market experienced a decline of 5.10% due to sluggish hospital equipment procurement and the impact of DRG 2.0 [4] - A recovery is anticipated in Q3 2025 as local fiscal pressures ease and medical equipment projects are initiated [4] Product Line Performance In Vitro Diagnostics (IVD) - The IVD segment grew by 10.82% in 2024, with international IVD growth exceeding 30% [5] - IVD revenue now constitutes 37.48% of total company revenue, surpassing the life information and support segment [5] Medical Imaging - The medical imaging segment grew by 6.60%, with international growth over 15% [7] - The launch of the high-end Resona A20 ultrasound is expected to enhance market presence [7] Life Information and Support - This segment saw a decline of 11.11%, although international growth was in double digits [8] - The company maintains a leading market share in domestic monitoring and respiratory devices despite challenges [8] Research and Development - R&D investment for 2024 was 4.008 billion CNY, accounting for 10.91% of revenue, while Q1 2025 saw 847 million CNY in R&D, representing 10.28% of revenue [11] - New product launches include advanced systems in life information and support, IVD, and medical imaging [12][13] Sustainability Efforts - The company received an AA rating from MSCI ESG and was included in the S&P Global Sustainable Development Yearbook [14] - Carbon emissions intensity decreased by 11.6% compared to 2021, with ongoing projects contributing to sustainability goals [15] Future Outlook - The company anticipates a significant recovery in domestic revenue starting Q3 2025, driven by the resumption of medical equipment projects [10] - Long-term growth strategies focus on digitalization, internationalization, and enhancing the supply chain to adapt to changing market conditions [24][25]